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Dr Steven R. DeMeester (Los Angeles, Calif). I congratulate
Dr Fabian and coauthors on an excellent manuscript and
presentation.
In this study, the authors address a clinically important issue—
what to dowith SMPLC by assessing the survival after resection of
these simultaneous lesions. Although the title indicates that the pa-
tients were N2 node negative, there were in fact 2 patients who had
positive N2 nodes. Why were these patients included in your anal-
ysis? Were these patients who did not have mediastinoscopy?
Should mediastinoscopy be essential in all of these patients?
Dr Fabian. That is a good point. We elected to include them be-
cause they cover the gamut of the disease that we deal with. Both
patients had bilateral tumors. Both had mediastinoscopy preoper-
atively, which discovered single-station N2 disease. Both patients
underwent neoadjuvant therapy preoperatively, subsequent restag-
ing, and then resection.
Dr DeMeester. Second, you mentioned that the synchronous
cancers were detected preoperatively, intraoperatively, or on final
pathologic examination. Did you evaluate survival on the basis of
how the lesion was found? In other words, if it was found patholog-
ically, did that imply a different survival than if it was known552 The Journal of Thoracic and Cardiovascular Surgpreoperatively? Did the number of lesions affect survival in these
patients?
Dr Fabian. That is a very good point. We did not look at it.
We do know that in the overwhelming majority of our patients
in this series, we had the knowledge of preoperative diagnosis,
particularly 44 with bilateral tumors. As well as the majority
of the 18 ipsilateral lesions in different lobes. There were only
5 ipsilateral same lobe so I don’t think we could determine
much from these data. But I do think it is a good point and worth
considering.
Dr DeMeester. The data presented by your group as well as
from previous publications all show that the histologic type of
the lesions does not significantly affect survival. Do you recom-
mend making any attempt to identify the histologic type preoper-
atively, and why exclude patients with ipsilateral same-histology
lesions?
Dr Fabian. The reason for excluding ipsilateral same-histology
lesions is that the current surgical recommendations are widely es-
tablished in both T3 and T4 lesions. The purpose of excluding
those patients here was to confirm as best we were able what the
true survival was for synchronous and avoid falsely including sat-
ellite nodules and metastatic nodules.
Dr DeMeester. From a mechanistic standpoint, it is logical that
most patients with synchronous lung cancers that are indeed sec-
ond primary tumors should be cigarette smokers, whereas in pa-
tients who are not cigarette smokers, you may suspect these
other lesions represent metastatic lesions. How many patients in
this series were cigarette smokers and did you analyze the outcome
in nonsmokers to see whether indeed we should not be resecting
multiple lesions in nonsmokers?
Dr Fabian. That is a very interesting point. The patients from St
Raphael’s and Albany Medical Center all were smokers. I cannot
comment on the University of Alabama smoking percentage and
we did not look at that specifically. Although if we accept radon
as being the largest risk factor for nonsmoker development of
non-small cell lung cancer, I believe that they may also have the
risk for the development of synchronous tumors. The primary dif-
ference is the distribution, which I understand to be the lower lobe
lung fields.
DrDeMeester. Last, could you describe your operative strategy
for patients with preoperatively detected synchronous bilateral le-
sions? Was median sternotomy and simultaneous resection used,
or were these all staged procedures? How did the characteristics
of the lesions affect the surgical approach? How did you choose
to do lobectomy or bilobectomies versus lesser resections in these
patients?
Dr Fabian. All of the bilateral lesions were approached as
staged procedures. No sternotomies were performed. As far as pre-
operative planning, there are 2 approaches. My personal method is
to approach the tumor that is most likely to increase the stage of
disease and therefore obviate the need for the second operation.
Having said that, the majority of the other surgeons who included
their patients in this series took the opposite approach, which was
to deal with the smaller lesion that would most likely get the pa-
tient through the second operation: if it was a planned sublobar
or superior segementectomy on one side in a lobe, they would ap-
proach the smaller tumor first. We actually looked at whether or
not the lower pathologic stage versus the higher pathologic stageery c September 2011
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Sinfluenced the interval between operations, and although there was
a trend, it did not meet statistical significance.
Dr Douglas E. Wood (Seattle, Wash). Dr Fabian, this was
a great presentation on a very important topic. I only wish you
were presenting it to a group of pulmonologists or medical oncol-
ogists rather than to this audience, which I think understands the
principles fairly well.
I agree with Dr DeMeester’s question about your exclusion of
ipsilateral same-histology tumors, which obviously are just as
likely to be synchronous tumors rather than satellite lesions. I think
you may have lost some numbers and some additional ability to
evaluate those. I guess I encourage you and Dr Cerfolio to poten-
tially reconsider that decision and to include those patients.
In our own practice, we have used the lack of N2 disease and the
lack of other metastatic disease as strong surrogates for synchro-
nous rather than metastatic cancers. That is similar to the conclu-
sion you have reached here; yet only a majority, but not every
patient, had a PET scan, mediastinoscopy, and brain MRI, which
would be the main criterion for eliminating the possibility that
these patients actually have metastatic disease. I think you ad-
dressed that in your conclusions, but can you reaffirm for me
what your principle is now for managing these patients? Would
they all receive each of those 3 modalities for lymph node and dis-
tant disease staging?
Dr Fabian. That is a valid point and thank you for your com-
ments. Specifically with regard to preoperative staging, it is crit-
ical that patients have both an integrated PET/CT scan as well as
mediastinoscopy and brain imaging, as you have pointed out.
Mediastinoscopy is probably the most critical component. In
my practice, I am not willing to substitute endobronchial ultra-
sound because of potential false-positive results. In the setting
of a PET scan that shows no evidence of mediastinal adenopathy,
I think those patients also need mediastinoscopy. My approach
is for all 3. However, I will give you an example of a patient.
In a patient with bilateral suspicious nodules, it wouldn’t be un-
reasonable to pursue a right side diagnostic thoracoscopy and
perform a lymphadenectomy if, in fact, it proves to be a malignant
nodule. I think for me in that patient it suffices to supplant the
mediastinoscopy in that particular scenario. As far as simple pro-
cedures preoperatively, I think mediastinoscopy should be used
routinely.
Dr Wood. I guess I would still argue that if you had done a me-
diastinoscopy and therewas a node positive, you could have forgone
the minimally invasive but still more invasive video-assisted tho-
racic surgical approach to pulmonary resection, which that patient
would not have benefited from, so you learned it retrospectively
rather than prospectively.
The last point I would make is to consider simultaneous proce-
dures in at least in some of these patients. Some patients can have
simultaneous rather than staged procedures even if they haveThe Journal of Thoracic and Cabilateral disease, without even a median sternotomy but with bilat-
eral approach. I would encourage you and Dr Cerfolio to add that
into your consideration for managing these patients.
Dr Fabian. I agree and again thank you for the comments. One
of the limitations of this study was in data supporting recommen-
dations regarding surgical approaches. I have no argument or data
to argue against simultaneous procedures and believe it is a per-
fectly acceptable way to treat these patients.
Dr Paul Schipper (Portland, Ore). My question is along the
same lines as Dr Wood’s and Dr DeMeester’s in thinking about
systemic versus localized disease. Suppose you have a patient
who has bilateral primaries and you think they are synchronous.
The N2 nodes are negative, and you have done the mediastino-
scopy and endobronchial ultrasound. When you resect the first
one, you find that there are in fact N1 nodes that are positive at
level 11 or level 12, or you find a third nodule that is of the
same histologic type, now an ipsilateral nodule. With this new ev-
idence of metastatic disease but no N2 disease, something consid-
ered less ominous in the staging system, would you continue on
with that second side at a later time or would you stop? Would
you say, this is systemic disease; maybe they need some chemo-
therapy and no more surgery?
Dr Fabian. I think that question runs the gamut. During the
bronchoscopy and mediastinoscopy, I try to establish the histo-
logic type of both lesions, whether with biopsy, brushings, or
washings this can be very helpful.
I think that, if a patient presented with T3 right upper lobe dis-
ease with the same histologic type, the indication is still for surgi-
cal resection of the contralateral side and we had patients in this
series like that. Of course, there are other considerations but
when falsely labeling someone with systemic or metastatic disease
ensures a poor outcome I think resection after prudent consider-
ation is still appropriate.
Dr Schipper. If the N1 node is positive at the time of your re-
section, would you resect the second lesion on the other side?
Dr Fabian. I would.
Dr Joseph Shrager (Stanford, Calif). You really went to great
pains to describe the tumors studied here as non-BAC, whereas to
me BAC is maybe even the more interesting group and certainly
the group we see more often. I am wondering how sure you are
they are actually non-BAC. Did you go back and have the pathol-
ogist look at the periphery of the tumors for a BAC component, or
did you reexamine the CT scans to see whether there was any
ground glass in the lesions?
Dr Fabian. We did, and I think that is a valuable question.
There are patients here whose pathology was reviewed, particu-
larly in the cases that were interpreted as adenocarcinoma with
BAC features but no BACs.
Dr Schrager. No pure BACs?
Dr Fabian. No pure BACs.rdiovascular Surgery c Volume 142, Number 3 553
